Product Description
Norepinephrine, also called noradrenaline, is both a neurotransmitter and a hormone. As a neurotransmitter, it’s a chemical messenger that helps transmit nerve signals across nerve endings to another nerve cell, muscle cell or gland cell. As a hormone, it’s released by your adrenal glands, which are hat-shaped glands that sit on top of each kidney. (Sourced from: https://my.clevelandclinic.org/health/articles/22610-norepinephrine-noradrenaline)
Mechanisms of Action: SSR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Brazil, Poland, Spain
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Hypotension|Shock, Cardiogenic|Shock, Septic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NoVa | P3 |
Recruiting |
Shock, Septic |
2027-08-01 |
|
HYP-NOR | P3 |
Unknown Status |
Hypotension |
2027-06-30 |
|
CONTENTSS | P3 |
Unknown Status |
Shock, Septic |
2025-06-30 |
|
EPITUBE-HEART | P3 |
Active, not recruiting |
Unknown |
2023-02-20 |